Nanomedicine First-in-Human Research: Challenges for Informed Consent

Emanuel E. Wendler D. , and Grady C. , “What Makes Clinical Research Ethical?” JAMA 283, no. 20 (2000): 2701–2711.

U.S. Department of Health and Human Services, “Common Rule, 45 CFR 46.101–124,” Federal Register 56, no. 117 (June 18, 1991): 28012–28022.

King N. M. P. Henderson G. E. Churchill L. R. Davis A. M. Hull S. C. , and Nelson D. K. , “Consent Forms and the Therapeutic Misconception: The Example of Gene Transfer Research,” IRB: Ethics & Human Subjects Research 27, no. 1 (2005): 1–8.

Fatehi L. and Wolf S. M. , “Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field,” Journal of Law, Medicine & Ethics 40, no. 4 (2012): 716–750; Resnik D. B. and Tinkle S. S. , “Ethical Issues in Clinical Trials Involving Nanomedicine,” Contemporary Clinical Trials 28, no. 4 (2007): 433–441.

Maynard A. D. Warheit D. B. , and Philbert M. A. , “The New Toxicology of Sophisticated Materials: Nanotoxicology and Beyond,” Toxicological Sciences 120, no. S1 (2011): S109–S129.

See Fatehi , supra note 4.

Kimmelman J. and London A. J. , “Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty,” PLoS Medicine 8, no. 3 (2011): E1001010 (5 pages), available at <http://dx.doi.org/10.1371%2Fjournal.pmed.1001010> (last visited November 12, 2012); Kimmelman J. , “Recent Developments in Gene Transfer: Risk and Ethics,” BMJ 330, no. 7482 (2005): 79–82.

McGinn R. , “Ethical Responsibilities of Nanotechnology Researchers: A Short Guide,” Nanoethics 4, no. 1 (2010): 1–12; Wolf S. M. Ramachandran G. Kuzma J. , and Paradise J. , eds., “Symposium: Developing Oversight Approaches to Nanobiotechnology: The Lessons of History,” Journal of Law, Medicine & Ethics 37, no. 4 (2009): 543–789.

Kimmelman J. , “Missing the Forest: Further Thoughts on the Ethics of Bystander Risk in Medical Research,” Cambridge Quarterly of Healthcare Ethics 16, no. 4 (2007b): 483–90; Kimmelman J. , “Predicting Ethical and Safety Risks to Bystanders from Nanomedicine Research,” Journal of Law, Medicine & Ethics 40, no. 4 (2012): 841–847; Marchant G. , Applying Prudent Precaution to Nanomedicine Clinical Trials, this symposium; Ramachandran G. Howard J. Maynard A. , and Philbert M. , “Handling Worker and Third-Party Exposures in Nanomedicine Research,” Journal of Law, Medicine & Ethics 40, no. 4 (2012): 831–840.

McAulife M. E. and Perry M. J. , “Are Nanoparticles Potential Male Reproductive Toxicants? A Literature Review,” Nanotoxicology 1, no. 3 (2007): 204–10; Wiwanitkit V. Sereemaspun A. , and Rojanathanes R. , “Effect of Gold Nanoparticles on Spermatozoa: The First World Report,” Fertility and Sterility 91, no. 1 (2009): E7-e8, available at <http://www.sciencedirect.com/science/article/B6T6K-4RB5BNR-2/2/33a12feb54d3316276cbabaa2d9492b0> (last visited November 12, 2012).

Wolf S. M. Paradise J. Nelson C. A. Kahn J. P. Lawrenz F. , “Symposium: Incidental Findings in Human Subjects Research: From Imaging to Genomics,” Journal of Law, Medicine & Ethics 36, no. 2 (2008): 216–383.

Jotterand F. and Alexander A. A. , “Managing the 'Known Unknowns”: Theranostic Cancer Nanomedicine and Informed Consent,” in Biomedical Nanotechnology: Methods and Protocols (New York: Springer-Verlag, 2011): At Chapter 26.

King N. M. P. , “Defining and Describing Benefit Appropriately in Clinical Trials,” Journal of Law, Medicine & Ethics 28, no. 4 (2000): 332–343.

Dresser R. , “First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless,” Journal of Law, Medicine & Ethics 37, no. 1 (2009): 38–50; King N. M. P. and Cohen-Haguenauer O. , “En Route to Ethical Recommendations for Gene Transfer Clinical Trials,” Molecular Therapy 16, no. 3 (2008): 432–438.

Kass N. Taylor H. Fogarty L. Sugarman J. Goodman S. N. Goodwin-Landher A. Carducci M. , and Hurwitz H. , “Purpose and Benefits of Early Phase Cancer Trials: What Do Oncologists Say? What Do Patients Hear?” Journal of Empirical Research on Human Research Ethics 3, no. 3 (2008): 57–68; see King , supra note 3.

See King , supra note 13.

See King , supra note 3.

Appelbaum P. S. Roth L. H. , and Lidz C. , “The Therapeutic Misconception: Informed Consent in Psychiatric Research,” International Journal of Law and Psychiatry 5, No. 3-4 (1982): 319–29.

Churchill L. R. Nelson D. K. Henderson G. E. King N. M. P. Davis A. M. Leahey E. , and Wilfond B. S. , “Assessing Benefits in Clinical Research: Why Diversity in Benefit Assessment Can Be Risky,” IRB: Ethics & Human Research 25, no. 3 (2003): 1–8; Dresser R. , “The Ubiquity and Utility of the Therapeutic Misconception,” Social Philosophy & Policy 19, no. 2 (2002): 271–294; Henderson G. E. Easter M. M. , and Zimmer C. , “Therapeutic Misconception in Early Phase Gene Transfer Trials,” Social Science and Medicine 62, no. 1 (2006): 239–253; Kimmelman J. , “The Therapeutic Misconception at 25: Treatment, Research, and Confusion,” Hastings Center Report 37, no. 6 (2007): 36–42.

See Dresser , supra note 14; King and Cohen-Haguenauer , supra note 14; King , supra note 3; Fatehi , supra note 4.

Henderson G. E. Churchill L. R. Davis A. M. Grady C. Joffe S. , and Kass N. , “Clinical Trials and Medical Care: Defining the Therapeutic Misconception,” PLoS Medicine 4, no. 11 (2007): 1735–1738.

See Henderson , supra note 19; King , supra note 3.

Churchill L. R. Collins M. L. King N. M. P. Pemberton S. , and Wailoo K. , “Genetic Research as Therapy: Implications of ‘Gene Therapy’ for Informed Consent,” Journal of Law Medicine & Ethics 26, no. 1 (1998): 38–47.

See Kass , supra note 15; King , supra note 3.

Horng S. and Grady C. , “Misunderstanding in Clinical Research: Distinguishing Therapeutic Misconception, Therapeutic Misestimation, and Therapeutic Optimism,” IRB: Ethics & Human Research 25, no. 1 (2003): 11–16; Sulmasy D. P. Astrow A. B. He M. K. Sells D. M. Meropol N. J. Micco E. , and Weinfurt K. P. , “The Culture of Faith and Hope: Patients' Justifications for Their High Estimates of Expected Therapeutic Benefit When Enrolling in Early Phase Oncology Trials,” Cancer 116, no. 15 (2010): 3702–3711.

See Common Rule, supra note 2.

National Institutes of Health, “NIH Guidance on Informed Consent for Gene Transfer Research,” available at <http://www4.od.nih.gov/oba/RAC/ic> (last visited November 12, 2012).

See Kimmelman , supra note 7; King and Cohen-Haguenauer , supra note 14.

See McGinn , supra note 8.

Schenk-Braat E. A. van Mierlo M. M. Wagemaker G. Bangma C. H. , and Kaptein L. C. , “An Inventory of Shedding Data from Clinical Gene Therapy Trials,” Journal of Gene Medicine 9, no. 10 (2007): 910–921; King and Cohen-Haguenauer , supra note 14.

See sources cited in supra note 10.

Hacein-Bey-Abina S. Von Kalle C. Schmidt M. McCormack M. P. Wulffraat N. , and Leboulch P. , “LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1,” Science 302, no. 5645 (2003): 415–419.

Capron A. , “Informed Consent in Catastrophic Disease Research and Treatment,” University of Pennsylvania Law Review 123, no. 2 (1974): 340–438.